Wet Age-related Macular Degeneration

Showing 1 - 25 of 44

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Wet Age-related Macular Degeneration Trial in Beijing (RC28-E, Aflibercept)

Recruiting
  • Wet Age-related Macular Degeneration
  • Beijing, Beijing, China
    Beijing Hospital
Feb 3, 2023

Data of Intravitreal Aflibercept Injection in Patients of Wet

Completed
  • Wet Age-related Macular Degeneration
  • Aflibercept (Eylea, BAY86-5321)
  • Multiple Locations, India
    Many Locations
Feb 2, 2023

s in Wet Age-related Macular Degeneration Which Have Never

Active, not recruiting
  • Wet Age-related Macular Degeneration
  • Aflibercept (Eylea, BAY86-5321)
  • Multiple Locations, Argentina
  • +16 more
Jan 16, 2023

Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema Trial in United States (KSI-301)

Terminated
  • Wet Age-related Macular Degeneration
  • +2 more
  • Phoenix, Arizona
  • +10 more
Nov 1, 2022

Wet Age-related Macular Degeneration Trial in United States (Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)

Recruiting
  • Wet Age-related Macular Degeneration
  • Melbourne, Florida
  • +4 more
Aug 18, 2022

Wet Age-related Macular Degeneration Trial (Ranibizumab, SCT510A)

Not yet recruiting
  • Wet Age-related Macular Degeneration
  • (no location specified)
Jul 28, 2022

Wet Age-related Macular Degeneration Trial in United States (EYP-1901)

Completed
  • Wet Age-related Macular Degeneration
  • Phoenix, Arizona
  • +10 more
Jul 25, 2022

Wet Age-related Macular Degeneration Trial in Beijing, Wuhan, Shanghai (CMAB818, Lucentis®)

Recruiting
  • Wet Age-related Macular Degeneration
  • Beijing, Beijing, China
  • +3 more
Jun 14, 2022

AMD, nAMD, Wet Age-related Macular Degeneration Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®))

Recruiting
  • AMD
  • +5 more
  • RGX-314 Dose 1
  • +2 more
  • Encino, California
  • +16 more
Jun 2, 2022

Wet Age-related Macular Degeneration Trial in Puerto Rico, United States (KSI-301, Aflibercept, Sham Procedure)

Active, not recruiting
  • Wet Age-related Macular Degeneration
  • Phoenix, Arizona
  • +65 more
Jun 2, 2022

Wet Age-related Macular Degeneration Trial in Boston, Worcester (Intravitreal anti-VEGF, Intravitreal AAVCAGsCD59, Oral

Completed
  • Wet Age-related Macular Degeneration
  • Intravitreal anti-VEGF
  • +2 more
  • Boston, Massachusetts
  • +1 more
May 24, 2022

Wet Age-related Macular Degeneration Trial in Bern (Aflibercept, Brolucizumab, early treat and extend (T&E))

Enrolling by invitation
  • Wet Age-related Macular Degeneration
  • Bern, Switzerland
    Berner Augenklinik am Lindenhofspital
May 13, 2022

Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in Worldwide (SCD411, Aflibercept)

Active, not recruiting
  • Wet Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Beverly Hills, California
  • +139 more
May 11, 2022

Wet Age-related Macular Degeneration Trial in Beijing (Aflibercept)

Completed
  • Wet Age-related Macular Degeneration
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Apr 19, 2022

Wet Age-related Macular Degeneration Trial (SCB-420, Aflibercept)

Withdrawn
  • Wet Age-related Macular Degeneration
  • (no location specified)
Apr 12, 2022

Exudative Macular Degeneration, Wet Age-related Macular Degeneration Trial in Iowa City (Doxycycline Hyclate, Placebo)

Recruiting
  • Exudative Macular Degeneration
  • Wet Age-related Macular Degeneration
  • Doxycycline Hyclate
  • Placebo
  • Iowa City, Iowa
    University of Iowa Hospitals & Clinics Department of Ophthalmolo
Apr 5, 2022

Wet Age-related Macular Degeneration Trial in Chengdu (MW02, Lucentis)

Recruiting
  • Wet Age-related Macular Degeneration
  • Chengdu, Si Chuan, China
    West China Hospital of Sichuan University
Mar 17, 2022

Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)

Active, not recruiting
  • Wet Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • ADVM-022
  • Bakersfield, California
  • +10 more
Mar 21, 2022

s in Wet AMD in Active Smokers

Completed
  • Wet Age-related Macular Degeneration
  • Medical Data extraction
  • Brussels, Belgium
    CHU Brugmann
Mar 7, 2022

Wet Age-related Macular Degeneration Trial in Hungary, Latvia, United States (Zimura, Lucentis)

Completed
  • Wet Age-related Macular Degeneration
  • Phoenix, Arizona
  • +27 more
Feb 3, 2022

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Enrolling by invitation
  • Wet Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • ADVM-022
  • Bakersfield, California
  • +8 more
Dec 23, 2021

Wet Age-related Macular Degeneration Trial in China (2.5mg of BAT5906, 4mg of BAT5906)

Completed
  • Wet Age-related Macular Degeneration
  • 2.5mg of BAT5906
  • 4mg of BAT5906
  • Beijing, Beijing, China
  • +15 more
Nov 30, 2021

Healthy Volunteers, Wet Age-related Macular Degeneration Trial in Fukuoka (Placebo, KHK4951)

Recruiting
  • Healthy Volunteers
  • Wet Age-related Macular Degeneration
  • Fukuoka, Japan
    Hakata clinic
Nov 10, 2021

Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration Trial in United

Recruiting
  • Neovascular Age-related Macular Degeneration
  • +2 more
  • RGX-314
  • Phoenix, Arizona
  • +12 more
Oct 12, 2021

Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration Trial in United States (RGX-314)

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration
  • RGX-314
  • Santa Barbara, California
  • +7 more
Apr 1, 2021